Marijuana became legal in Canada, so what can UNVC investors expect moving forward?
• Medical marijuana and potential involvement of Big Pharma.
• Sub-sectors, including CBD-oil, infused-beverages, edibles, various extraction plays, and 'craft' weed brands.
• The continued legalization and liberalization of laws towards medical and recreational cannabis globally. The most important market, by far, being the United States.
• Retail outlets and the potential emergence of chains. If a retail brand emerges quickly and establishes a regional or potentially national footprint, they could be ripe for acquisition from any of the major players - all of which will be hungry for more and more distribution.
While I do not expect Univec or any of the other companies in this group to be bought out at this time, the industry consolidation will likely increase the value of all players in this industry --- I don’t think selling off parts that fits with Crockett’s plan, but one never knows.
As we know, in June the U.S. Food and Drug Administration approved GW Pharmaceuticals Plc's Epidiolex to treat two rare forms of childhood epilepsy. It was the first medical treatment derived from the marijuana plant to get the greenlight for sale in the U.S. Also, British Columbia-based producer Tilray Inc. already has an agreement to develop products and delivery systems with Sandoz, the Canadian division of Novartis International AG of Switzerland.
These are two examples, but there is a suite of companies, universities, and countries exploring and testing the benefits of medical marijuana.
Canadian marijuana company, FSD Pharma is sponsoring a research program at Tel Aviv University utilizing a cannabinoid-based treatment focused on cardiovascular disease. Interestingly, the research program is designed "at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world," according to the company. It should be noted that Israel is one of the world's foremost biotech hubs, and is a leader in the study and development of cannabis treatments.
There have been encouraging studies out of the EU regarding cannabinoid-based therapies and the potential for reduced inflammation of the heart. Apparently, European research is finding that heart disease can be treated with cannabinoid products.
I am certain there is more, but this is a quick summary of what I found last night while ready about the industry. The exact areas that will effect Univec and companies is unknown at this time, but it appears we might be right in the middle of just about everything, and the major players will be looking on with envy at Univec and their HRI subsidiary. IMO
• Medical marijuana and potential involvement of Big Pharma.
• Sub-sectors, including CBD-oil, infused-beverages, edibles, various extraction plays, and 'craft' weed brands.
• The continued legalization and liberalization of laws towards medical and recreational cannabis globally. The most important market, by far, being the United States.
• Retail outlets and the potential emergence of chains. If a retail brand emerges quickly and establishes a regional or potentially national footprint, they could be ripe for acquisition from any of the major players - all of which will be hungry for more and more distribution.
While I do not expect Univec or any of the other companies in this group to be bought out at this time, the industry consolidation will likely increase the value of all players in this industry --- I don’t think selling off parts that fits with Crockett’s plan, but one never knows.
As we know, in June the U.S. Food and Drug Administration approved GW Pharmaceuticals Plc's Epidiolex to treat two rare forms of childhood epilepsy. It was the first medical treatment derived from the marijuana plant to get the greenlight for sale in the U.S. Also, British Columbia-based producer Tilray Inc. already has an agreement to develop products and delivery systems with Sandoz, the Canadian division of Novartis International AG of Switzerland.
These are two examples, but there is a suite of companies, universities, and countries exploring and testing the benefits of medical marijuana.
Canadian marijuana company, FSD Pharma is sponsoring a research program at Tel Aviv University utilizing a cannabinoid-based treatment focused on cardiovascular disease. Interestingly, the research program is designed "at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world," according to the company. It should be noted that Israel is one of the world's foremost biotech hubs, and is a leader in the study and development of cannabis treatments.
There have been encouraging studies out of the EU regarding cannabinoid-based therapies and the potential for reduced inflammation of the heart. Apparently, European research is finding that heart disease can be treated with cannabinoid products.
I am certain there is more, but this is a quick summary of what I found last night while ready about the industry. The exact areas that will effect Univec and companies is unknown at this time, but it appears we might be right in the middle of just about everything, and the major players will be looking on with envy at Univec and their HRI subsidiary. IMO
1
